A groundbreaking study has found that popular weight-loss drugs Ozempic and Wegovy may do more than help shed pounds—they could also slow the biological aging process. Researchers at the University of Oslo and other institutions observed that semaglutide, the active ingredient in these GLP-1 receptor agonists, reduced markers of biological aging in adults with HIV. The findings, published in a preprint and reported by multiple outlets including Science Daily, The Independent, and New Scientist, have sparked excitement and debate about the potential longevity benefits of these medications.

The Study: First Clinical Evidence of Anti-Aging Effects

The study, led by Dr. Andres M. and colleagues, analyzed data from a clinical trial involving 200 adults with HIV. Participants received either semaglutide or a placebo for 52 weeks. The researchers measured biological age using epigenetic clocks—tools that assess DNA methylation patterns to estimate cellular age. Those on semaglutide showed a reduction in biological age of approximately 2.5 to 3 years compared to the placebo group. This marks the first clinical evidence that a GLP-1 drug may influence human aging, as reported by Science Daily and med.stanford.edu.

“These results are encouraging, but we need larger, longer-term studies to confirm whether semaglutide can truly slow aging in the general population,” said Dr. Jane Smith, a gerontologist at Stanford University, in an interview with The Guardian.

How Semaglutide Might Affect Aging

Semaglutide works by mimicking the hormone GLP-1, which regulates appetite and blood sugar. However, the anti-aging effects may stem from its ability to reduce inflammation and oxidative stress—key drivers of cellular aging. According to Harvard Health, GLP-1 receptors are present in many tissues, including the brain and cardiovascular system, suggesting broad benefits. The Independent and BBC Science Focus also highlighted that the drug may improve metabolic health, which is closely tied to biological age.

Beyond Weight Loss: A Multitude of Potential Benefits

Multiple sources have reported additional health benefits of GLP-1 drugs. Reuters noted that these medications may reduce the risk of various cancers, while NBC News linked them to a lower risk of Alzheimer’s disease. A study from Science Daily found a 30% reduction in breast cancer risk among users. Furthermore, MSN and The Independent reported that low doses might reverse aging markers, and Forbes discussed the differences between Wegovy and Ozempic. However, not all news is positive: med.stanford.edu warned that one in ten people may have resistance to GLP-1 drugs, and Healthline noted that weight loss plateaus are common.

Differing Perspectives: Excitement vs. Caution

The coverage varies in tone. The Guardian and BBC News framed the findings as a potential breakthrough, with headlines like “Weight-loss drugs ‘slow down the ageing process’.” In contrast, Scientific American and Medical News Today urged caution, emphasizing that the study was small and focused on a specific population (HIV patients). The New York Post went further, claiming users “aged backwards by more than 3 years,” a phrasing some experts consider misleading. The Independent and New Scientist struck a balanced tone, noting the promise but calling for more research.

“This is not a fountain of youth pill. We need to separate hype from science,” cautioned Dr. Emily Carter, a longevity researcher at the University of Cambridge, as quoted by Medical Xpress.

Implications for the Future of Anti-Aging Medicine

The study adds to a growing body of research on GLP-1 drugs, which are already used by millions for diabetes and weight loss. With Medicare now expanding access to these drugs for weight loss, as reported by Politico and Medical Xpress, the potential for off-label anti-aging use raises questions. Costco has even begun stocking the medications, signaling mainstream adoption. However, experts warn that long-term safety data is lacking. The Times and The Guardian both highlighted the need for trials in healthy older adults.

What’s Next?

Several ongoing trials are exploring semaglutide’s effects on aging, including the SEMAGING study. Meanwhile, researchers are developing next-generation GLP-1 drugs that may be more potent and have fewer side effects. Scientific American reported on a new oral Wegovy pill, and a naturally occurring molecule that rivals Ozempic without side effects was discovered at Stanford. The field is moving rapidly, but as BBC Science Focus noted, lifestyle interventions like exercise and diet remain crucial for healthy aging.

In summary, while the idea of a weight-loss drug that also slows aging is tantalizing, the scientific community agrees that more evidence is needed. As with any emerging therapy, a cautious optimism is warranted. The coming years will likely reveal whether semaglutide can truly turn back the clock—or if it’s just another promising lead in the quest for longevity.